Reported 18 days ago
Despite an unexpected profit in Q3 2024, driven by higher COVID-19 vaccine sales, analyst Michael Yee warns that 2025 will pose 'fairly challenging' conditions for Moderna due to declining vaccination rates and continued scrutiny within the biotech sector.
Source: YAHOO